-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 28, Hengrui Medicine issued an announcement stating that it had recently received the "Drug Supplementary Application Approval Notice" for Fondaparinux Sodium Injection approved and issued by the State Food and Drug Administration, and the drug passed the consistency evaluation of generic drugs
The drug indications:
1.
2.
3.
Fondaparinux is a synthetic, selective inhibitor of activated factor X.
Fondaparinux was jointly developed by Organon and Sanofi.
Data show that the global sales of Fondaparinux sodium injection in 2020 will be approximately US$191 million